Cullinan Therapeutics (CGEM) vs Surrozen (SRZN)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.
Summary
Surrozen (SRZN) has outperformed Cullinan Therapeutics (CGEM) over the past year, gaining 115.6% versus a loss of 6.1%. Over five years, CGEM leads with a -51.2% price change compared with -79.0% for SRZN. Surrozen is the larger company by market cap ($596.4 million vs $577.1 million), about 1.0 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | CGEM | SRZN |
|---|---|---|
| Share price | $8.89 | $28.46 |
| Market cap | $577.15M | $596.40M |
| 1-day change | -1.98% | -7.21% |
| YTD return | -14.11% | +25.93% |
| 1-year return | -6.12% | +115.61% |
| 5-year return | -51.21% | -78.97% |
| EPS (TTM) | $-3.09 | $-41.94 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| Revenue (latest FY) | — | $3.48M |
| Revenue growth (YoY) | — | -67.37% |
| Net income (latest FY) | $-219.88M | $-242.03M |
| Operating margin | — | -1210.58% |
| Net margin | — | -6960.77% |
| 52-week high | $23.19 | $37.83 |
| 52-week low | $8.47 | $12.79 |
| Distance from 52-week high | -61.66% | -24.77% |
| Analyst consensus | strong_buy | strong_buy |
| Avg. price target upside | +285.49% | +123.12% |
| Average volume | 997.14K | 537.16K |
| Shares outstanding | 64.92M | 20.96M |
| Employees | 109 | 44 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) | Biotechnology: Biological Products (No Diagnostic Substances) |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- SRZN has outperformed CGEM by 121.7 percentage points over the past year.
About Cullinan Therapeutics
CGEM stock →Cullinan Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops therapies for autoimmune diseases and cancer in the United States. It engages in the development of CLN-978, a CD19xCD3 bispecific T cell engager for autoimmune diseases in Phase 1 clinical trials; Velinotamig, a BCMAxCD3 bispecific T cell in Phase 1 clinical trials in patients with autoimmune diseases; and CLN-049, a FLT3xCD3 bispecific T cell engager, which is in Phase 1 clinical trials in patients with relapsed and refractory acute myeloid leukemia or myelodysplastic syndrome.
Health Care · Biotechnology: Biological Products (No Diagnostic Substances) · 109 employees
About Surrozen
SRZN stock →Surrozen, Inc., a biotechnology company, discovers and develops product candidates to selectively modulate the Wnt pathway for tissue repair. Its lead product candidates are antibody-based therapeutics that target various disease areas, including diseases of the eye, intestine, liver, lung, retina, kidney, cochlea, cornea, skin, pancreas, and central nervous system.
Health Care · Biotechnology: Biological Products (No Diagnostic Substances) · 44 employees
CGEM vs SRZN FAQ
Which is bigger, Cullinan Therapeutics or Surrozen?
Surrozen (SRZN) is larger, with a market capitalization of $596.40M compared with $577.15M for Cullinan Therapeutics (CGEM).
Which stock has performed better over the past year, CGEM or SRZN?
SRZN returned +115.61% over the past 12 months, compared with -6.12% for CGEM (price return, excluding dividends). Past performance does not predict future results.
Are Cullinan Therapeutics and Surrozen in the same industry?
Yes. Both are classified in the Biotechnology: Biological Products (No Diagnostic Substances) industry within the Health Care sector.